HR+, HER2– Early Breast Cancer Education: CDK4/6 Inhibitors

Stephen Johnston, a medical oncologist at the Royal Marsden Hospital in London, outlines the data supporting CDK4/6 inhibitors plus endocrine therapy in patients with high-risk, hormone positive, HER2-negative breast cancer. This is especially important for patients with high-risk disease, where adding another therapy could decrease their risk of disease recurrence.

Highlights

• Most recent efficacy and safety data from monarchE and NATALEE presented at ESMO 2025
• Seven year analysis of monarchE trial
• Five year analysis of NATALEE trial
• Dose reduction data

Want to learn more? Access additional EBC medical education resources here.